Limagrain Moves GM Tests To The US due to French ban & decontaminations

FRANCE: Feb­ru­ary 29, 2008
PARIS — Europe’s largest seed coop­er­a­tive Lima­grain said on Thurs­day it had moved its research tests into genet­i­cal­ly mod­i­fied (GM) crops to the Unit­ed States, put off by France’s hos­til­i­ty to GMs and the destruc­tion of test fields.

FRANCE: Feb­ru­ary 29, 2008
PARIS — Europe’s largest seed coop­er­a­tive Lima­grain said on Thurs­day it had moved its research tests into genet­i­cal­ly mod­i­fied (GM) crops to the Unit­ed States, put off by France’s hos­til­i­ty to GMs and the destruc­tion of test fields.

Chair­man Pierre Pagesse said Bio­gem­ma, Lima­grain’s grain and oilseed research unit, would car­ry around 1,000 tests on GM crops this year in Illi­nois, in the US corn belt.

Lima­grain has a 70 per­cent stake in the world’s fourth-largest seed mak­er Vil­morin.

“We have decid­ed to trans­fer our tests to the Unit­ed States this year,” Pagesse told Reuters in an inter­view at the Paris farm show.

“It is with a heavy heart,” he added. “For the first time we will move out­side France and even out­side the Euro­pean Union to car­ry out our tests and this due to the cur­rent sit­u­a­tion in our coun­try,” Pagesse said.

While GM crops are com­mon in the Unit­ed States, France and oth­er Euro­pean coun­tries are dubi­ous about using the new genet­ic tech­nol­o­gy in agri­cul­ture.

France decid­ed in Decem­ber to sus­pend the cul­ti­va­tion of the sole GM crop grown in the Euro­pean Union, a maize devel­oped by US biotech giant Mon­san­to, and noti­fied the Euro­pean Com­mis­sion ear­li­er this month that it was extend­ing the ban.

Pagesse said the expa­tri­a­tion of the GM tests to the Unit­ed States, was also prompt­ed by the repet­i­tive attacks car­ried out by anti-GM activists on Bio­gem­ma’s test fields.

CONTRADICTION

The deci­sion, although not irre­versible, will inevitably affect the work­ing of Lima­grain, which owns 55 per­cent of Bio­gem­ma and total­ly relies on the com­pa­ny for its GM research, he said.

“I know that to move the intel­lec­tu­al part of the group is to move the group’s epi­cen­tre in time,” he said, stress­ing that the com­pa­ny had prob­a­bly wait­ed too long to make the move.

Lima­grain would keep doing non-GM tests in France but all biotech research, car­ried out through Bio­gem­ma, would be done in the Unit­ed States, which in the end could penalise Europe as seeds may not be adapt­ed to Euro­pean soil and pests, he said.

“The com­pa­ny keeps its knowl­edge but it’s the French peas­ants who are going to lose out,” he said.

Pagesse argued there was a con­tra­dic­tion between the French ban on the grow­ing of GM maize and mas­sive­ly import­ing genet­i­cal­ly mod­i­fied ani­mal feed.

“Either it is bad and we should hur­ry ban­ning imports or we con­sid­er that it’s good for con­sumers, includ­ing through ani­mal feed, then we should let French farm­ers use the tech­nolo­gies that we think are bet­ter adapt­ed,” he said.

A gov­ern­ment-appoint­ed com­mit­tee of sci­en­tists, farm­ers, politi­cians and non-gov­ern­men­tal organ­i­sa­tions said in Jan­u­ary “seri­ous doubts” remained over whether the MON 810 was safe.

The main wor­ry men­tioned in the report, which trig­gered the gov­ern­men­t’s deci­sion on the ban, con­cerned dis­sem­i­na­tion to oth­er crops and bio­di­ver­si­ty, not human health.